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Introduction
According to the World Health Organization, 63% of the 
57 million deaths in 2008 were due to noncommunicable 
diseases [1]. Of these, cardiovascular (CV) diseases were 
the most common, accounting for approximately 30% of 
all deaths globally, followed by cancers (13%), chronic 
lung diseases (7%) and diabetes (2%). Whilst non-
communicable disease mortality rates have fallen in the 
developed world during recent years, rates continue to 
increase in lower income populations, with approximately 
80% of all noncommu ni cable disease deaths occurring in 
low-income and middle-income countries. Of these 
deaths, 29% occur in people under the age of 60 years.
Of the 17.3 million CV deaths in 2008, 7.3 million were 
due to coronary heart disease and 6.2 million were due to 
stroke [2]. Major modiﬁ able risk factors for CV disease 
and other noncommunicable diseases include hyper-
tension, dyslipidemia, tobacco use, low fruit–vegetable 
intake, alcohol use, physical inactivity and high body 
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mass index. Rather than existing in isolation, these risk 
factors tend to occur in clusters [3]. Data from the 
National Health and Nutrition Examination Survey (1999 
to 2000) showed that 93.1%, 73.0%, and 35.9% of US 
adults had ≥1, ≥2, and ≥3 modiﬁ able risk factors for CV 
disease, respectively [4]. Since each additional risk factor 
has a multiplicative, rather than an additive, eﬀ ect on 
vascular risk [5], patients with clusters of risk factors 
have a signiﬁ cantly increased risk of developing CV and 
cerebrovascular disease. Metabolic syndrome (MetS), for 
example  – charac ter ized by three or more of the 
following: abdominal obesity, atherogenic dyslipidemia, 
hypertension, and/or insulin resistance with or without 
glucose intolerance [6-10] – is associated with a twofold 
to fourfold increased risk of stroke, a threefold to fourfold 
increased risk of myocardial infarction [11,12], and a 
ﬁ vefold to ninefold higher risk of developing type 2 
diabetes (T2D) [13]. Similarly, T2D is associated with a 
twofold to fourfold increased risk of CV death [14]. Given 
that many CV risk factors are silent, patients with 
individual risk factors should be assessed for their overall 
cardiometabolic proﬁ le and treated accordingly.
Th e recommended treatment for MetS is lifestyle 
change, focusing on weight loss and physical activity, 
followed by pharmaceutical treatment for the individual 
risk factors [6,8-10]. Dyslipidemia  – an imbalance 
between the proatherogenic apolipoprotein-B-containing 
lipoproteins (low-density lipoproteins, very-low density 
lipoproteins and chylomicrons/chylomicron remnants) 
and anti-atherogenic high-density lipoproteins (HDLs) – 
is a major risk factor for CV and cerebrovascular disease 
[5,15]. Numerous studies show that lowering low-density 
lipoprotein-cholesterol (LDL-C) levels using statins can 
signiﬁ cantly reduce CV risk in people with and without 
T2D, with no lower limit beyond which LDL-C-lowering 
is not beneﬁ cial [16-23]. Based on these results, most 
international treatment guidelines recommend lowering 
LDL-C to <2.6  mmol/l (100  mg/dl) in patients with 
established CV disease and to <1.8 to 2.0 mmol/l (70 to 
80 mg/dl) in those with very high CV risk, reducing total 
cholesterol to <4.5 mmol/l (174 mg/dl) with an option of 
<4  mmol/l (154  mg/dl) if feasible [6,9,24-26]. Although 
most statins (including atorvastatin, simvastatin and 
pitavastatin) have similar eﬀ ects on LDL-C levels [27-37], 
diﬀ er ences in chemical structure and pharmacokinetic 
proﬁ le can lead to variations in pleiotropic eﬀ ects, 
adverse event proﬁ les and drug–drug interactions. Th e 
choice of statin should therefore depend on the 
characteristics and needs of the individual patient.
Despite the widespread availability of eﬀ ective lipid-
lowering drugs, the prevalence of hypercholesterolemia 
varies considerably throughout Europe, ranging from 3 to 
53% in men and from 4 to 40% in women, depending on 
the country [38]. In most populations, almost 50% of 
people treated with lipid-lowering drugs have a total 
cholesterol level >6.5 mmol/l (251 mg/dl), suggesting that 
greater eﬀ orts are needed to identify and adequately treat 
people with hypercholesterolemia. Moreover, even in 
patients that fully attain their total cholesterol/LDL-C 
targets, the risk of major vascular events is only reduced 
by around one-third [17], leaving substantial residual 
risk. Th e identiﬁ cation and treatment of residual risk 
factors is therefore essential for the eﬀ ective management 
of CV disease.
The importance of high-density lipoprotein for 
reducing residual risk
Numerous studies have shown that low levels of high-
density lipoprotein-cholesterol (HDL-C) (deﬁ ned as 
<1 mmol/l; 40 mg/dl in men, and <1.3 mmol/l; 50 mg/dl in 
women) are independent risk factors for coronary heart 
disease [39-46]. Th e Emerging Risk Factors Collaboration 
analyzed records from 68 studies in 302,430 people 
without initial vascular disease and demonstrated that 
each 0.38 mmol/l (14 mg/dl) increase in HDL-C level was 
associated with a 22% reduction in coronary heart 
disease risk, irrespective of the triglyceride (TG) level 
(Figure  1) [42]. Consequently, the recent European 
Society of Cardiology/European Athero scler osis Society 
Guidelines for the Management of Dyslipid emia have 
included low HDL-C levels in their latest CV risk 
assessment charts [6,9,39]. Th is is particularly important 
for people with MetS or T2D who often have low levels of 
HDL-C accompanied by high levels of TG (≥1.7 mmol/l; 
150  mg/dl) and a preponderance of small, dense low-
density lipoprotein particles that can result in an 
underestimation of risk based solely on LDL-C. Th is triad 
of lipid abnormalities has been called atherogenic 
dyslipidemia [47-49].
A number of therapeutic options are available for 
increasing HDL-C levels, including statins, ﬁ brates and 
niacin [6,39]. In general, niacin can increase HDL-C by 
10 to 25%. However, recent results from the AIM-HIGH 
and HPS-2 THRIVE studies showed that the additional 
increases in HDL-C achieved when extended-release 
niacin was added to a statin did not result in further 
reductions in CV events [50,51]. Fibrates, on the con-
trary, can increase HDL levels by 2 to 10% and have been 
shown to reduce CV risk in people with signiﬁ cantly 
elevated levels of TG and reduced levels of HDL-C 
[52-55]. For example, the Action to Control Cardio-
vascular Risk in Diabetes (ACCORD) study found that 
the primary event rate (a composite of nonfatal myo-
cardial infarction, stroke or CV death) was reduced from 
17.3% to 12.4% in the subgroup of T2D patients with 
both low baseline levels of HDL-C (≤34  mg/dl or 
0.88  mol/l) and high baseline TG (≥204  mg/dl or 
≥2.3 mmol/l) [52]. However, this study also showed that 
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the addition of fenoﬁ brate to conventional statin treat-
ment had no eﬀ ect on event rates in people with normal 
levels of TG and/or HDL-C.
To date, the only lipid-lowering studies in which drug-
induced elevations in HDL-C have been found to 
correlate with reductions in CV risk involve statins 
[56-60]. A post hoc analysis of the Treating to New 
Targets (TNT) trial conducted in 2,661 subjects achiev-
ing LDL-C <1.8 mmol/l (70 mg/dl) during treatment with 
atorvastatin 10 or 80 mg/day showed that HDL-C levels 
were predictive of major CV events across the entire 
cohort, both when HDL-C was considered a continuous 
variable and when subjects were stratiﬁ ed according to 
HDL-C quintile [56]. Th is relationship remained true 
even after event rates were adjusted for other risk factors, 
including baseline levels of LDL-C (Figure 2).
Consistent with this observation, a post hoc analysis of 
intravascular ultrasound data from 1,455 people in four 
prospective randomized clinical trials showed that statin-
associated changes in HDL-C were inversely associated 
with the progression of coronary atherosclerosis even in 
patients with low levels of LDL-C [61]. Th e proposed 
explanation for these ﬁ ndings is that statin-induced HDL 
elevations stimulate the ‘reverse cholesterol transport’ 
pathway, a process in which excess cholesterol is removed 
from peripheral cells and transported to the liver via 
HDL for excretion into bile [49]. Although most statins 
increase HDL-C levels to some extent, pitavastatin 
consistently produces signiﬁ cantly greater HDL eleva-
tions that are maintained, or increased, over time 
[29,58,60,62-64]. Pitavastatin is therefore likely to be 
particularly eﬃ  cacious in people with low levels of 
HDL-C, such as those with cardiometabolic disease.
In addition to their role in cholesterol homeostasis, 
HDL particles have been shown to reduce oxidation, 
reduce vascular inﬂ ammation and vascular thrombosis, 
to improve endothelial function and repair, and to 
regulate the function and survival of pancreatic β-cells 
[47,49,65]. Th ese functions are often defective in patients 
with inﬂ ammatory conditions such as MetS and T2D and 
can add to a patient’s overall CV risk. Recent studies have 
shown that, in addition to elevating HDL levels, some 
lipid-lowering agents are associated with pleiotropic 
eﬀ ects that improve HDL structure and function 
[47,49,66-68]. Th is observation is supported by a recent 
study, in which pitavastatin was associated with signiﬁ -
cantly greater reductions in plaque volume per 1% 
increase in HDL-C than other statins (atorvastatin, 
pravastatin, rosuvastatin, simvastatin) [67]. Future 
studies should therefore assess the eﬀ ects of statins on 
HDL quality as well as quantity.
Th e following reviews will discuss the potential beneﬁ ts 
of pitavastatin versus other statins in the treatment of 
patients with dyslipidemia, MetS or T2D, focusing on its 
Figure 1. High-density lipoprotein-cholesterol increase is associated with reduction in coronary heart disease risk, irrespective of 
triglyceride [42]. HDL-C, high-density lipoprotein-cholesterol.
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eﬀ ects on HDL-C quantity and quality, its impact on 
atherosclerosis and CV risk, and the avoidance of drug 
interactions. Recent controversies surrounding the 
potentially diabetogenic eﬀ ects of statins will also be 
discussed, with a focus on the possibility that pitavastatin 
diﬀ ers positively from other statins in this regard.
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